- Home
- ALLE vs PCVX Comparison
ALLE vs PCVX Comparison
Compare ALLE & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLE
- PCVX
- Stock Information
- Founded
- ALLE 2013
- PCVX 2013
- Country
- ALLE Ireland
- PCVX United States
- Employees
- ALLE N/A
- PCVX N/A
- Industry
- ALLE Diversified Commercial Services
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- ALLE Consumer Discretionary
- PCVX Health Care
- Exchange
- ALLE Nasdaq
- PCVX Nasdaq
- Market Cap
- ALLE 10.9B
- PCVX 9.6B
- IPO Year
- ALLE N/A
- PCVX 2020
- Fundamental
- Price
- ALLE $130.48
- PCVX $37.76
- Analyst Decision
- ALLE Hold
- PCVX Strong Buy
- Analyst Count
- ALLE 6
- PCVX 9
- Target Price
- ALLE $137.67
- PCVX $147.50
- AVG Volume (30 Days)
- ALLE 1.1M
- PCVX 1.6M
- Earning Date
- ALLE 04-24-2025
- PCVX 05-07-2025
- Dividend Yield
- ALLE 1.57%
- PCVX N/A
- EPS Growth
- ALLE 11.44
- PCVX N/A
- EPS
- ALLE 6.82
- PCVX N/A
- Revenue
- ALLE $3,772,200,000.00
- PCVX N/A
- Revenue This Year
- ALLE $4.37
- PCVX N/A
- Revenue Next Year
- ALLE $4.22
- PCVX N/A
- P/E Ratio
- ALLE $18.81
- PCVX N/A
- Revenue Growth
- ALLE 3.33
- PCVX N/A
- 52 Week Low
- ALLE $113.27
- PCVX $30.12
- 52 Week High
- ALLE $156.10
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- ALLE 54.19
- PCVX 15.46
- Support Level
- ALLE $125.63
- PCVX $68.36
- Resistance Level
- ALLE $131.64
- PCVX $76.61
- Average True Range (ATR)
- ALLE 2.54
- PCVX 3.45
- MACD
- ALLE 0.40
- PCVX -2.06
- Stochastic Oscillator
- ALLE 85.77
- PCVX 16.43
About ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2023, Allegion generated 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy and Switzerland-based Dormakaba.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.